Jul 27, 2025, 16:44

Quality Improvement Grant: Enhancement of Breast Cancer Management in French-speaking Sub-Saharan Africa

Pfizer, in collaboration with the Association Marocaine de Recherche et de Formation en Oncologie Médicale (AMFROM), invites proposals for quality improvement initiatives aimed at optimizing breast cancer care—through culturally appropriate education, streamlined referral pathways, and workforce training—in Mali, Senegal, DRC, Togo, and Benin .

Eligibility Criteria:

Applicants must be organizations (not individuals or independent physician groups), such as professional schools (medical, dental, nursing, allied health, pharmacy), healthcare institutions, professional societies, or government agencies.
Collaborations within and between institutions are encouraged; the prime applicant must have a defined leadership role.
The Project Lead/PI must be an employee or contractor of the requesting organization.
Requesting organizations must be legally able to receive direct grant funding from Pfizer Inc. .

Funding Details:

Individual projects may request up to USD 50,000; maximum project duration is two years.
Total budget available under this RFP is approximately USD 150,000.
Award amounts include direct costs plus institutional overhead (capped at 28%).
Funds may support project design, implementation, and evaluation but not capital purchases or Pfizer product procurement. .

Deadline:

Applications must be submitted by July 25, 2025, 23:59 Eastern Standard Time (GMT −5) .

Where to Go for Further Information:

Submit online via the CyberGrants portal and click “Start a New Quality Improvement Application.”
Select Primary Area of Interest: Oncology – Breast – QI, then Competitive Grant Program Name: “2025 ONC SSA AMFROM Breast Cancer QI.”
For RFP questions, contact Rehab Elsaie at [email protected] (subject: “Enhancement of Management of breast cancer in French speaking Sub-Saharan African Countries 2025”). .

AMFROM Benin Breast Cancer cancer Democratic Republic of the Congo Mali OncoDaily Oncology pfizer professional education Quality Improvement referral pathways Senegal Sub-Saharan Africa Togo

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth